Home

Mary Kay Fenton

CIK 1378589 · Chief Financial Officer · last filed 2026-07-02

Mary Kay Fenton is a Chief Financial Officer who has filed 34 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing shows the insider was granted $13.3K of CGEM on Jul 2, 2026. Across all open-market trades the lifetime net is −$972.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.7M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.69M

Companies

5

Total Filings

34

Lifetime Open-Market Net

-$972.1K

Filer Profile

Reported Address
C/O CULLINAN THERAPEUTICS, INC.
1 MAIN ST SUITE 1350
CAMBRIDGE, MA 02142
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CGEM Chief Financial Officer 127,921 $21.00 $2.69M -$59.9K 6 2026-07-02
Tourmaline Bio, Inc. (TALS) Delisted Chief Financial Officer 6,805 $27.20 $185.1K $0 4 2023-07-06
Oncorus, Inc. (ONCR) Delisted Director — $0.12 — $0 2 2022-06-24
ACHILLION PHARMACEUTICALS INC (ACHN) Delisted Chief Financial Officer 2,500 — — -$912.2K 17 2018-02-13
ACHILLION PHARMACEUTICALS INC (TPTX) Delisted Vice President and CFO 1,257 $76.01 $95.5K $0 4 2008-12-17

Recent Filings

34 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-02 CGEM Grant (A) +1,541 $13.3K EDGAR
2026-02-23 CGEM Sell (S) −4,398 -$59.9K EDGAR
2026-02-19 CGEM Grant (A) +68,750 $0 EDGAR
2026-01-05 CGEM Grant (A) +27 $175 EDGAR
2025-02-21 CGEM Grant (A) +60,000 $0 EDGAR
2024-04-30 CGEM Grant (A) — $0 EDGAR
2023-07-06 Tourmaline Bio, Inc. (TALS) Delisted Tax (F) −12,946 -$39.9K EDGAR
2023-07-05 TRML Notice (144) −12,946 -$39.9K EDGAR
2023-02-03 Tourmaline Bio, Inc. (TALS) Delisted Grant (A) — $0 EDGAR
2022-09-13 Tourmaline Bio, Inc. (TALS) Delisted Grant (A) +80,000 $0 EDGAR
Showing 1–10 of 34
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.